Skip to main content
SpringerLink
Log in

Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Insulin resistance plays a major role in the pathogenesis of polycystic ovary syndrome (PCOS). Therefore, there is a growing interest in the use of insulin sensitizer drugs in the treatment of PCOS. Research in recent years has shown that sitagliptin has been reported to improve ovarian cycles and ovulation in PCOS patients.

Aims

We aimed to compare the effects of metformin and sitagliptin on PCOS individuals undergoing ICSI.

Methods

Sixty PCOS patients were divided into 3 groups: metformin, sitagliptin, and placebo group. Treatment was carried out 2 months before the start of the ovulation cycle and continued until the day of oocyte aspiration. The serum levels of total testosterone, estradiol, and fasting insulin along with the total number of retrieved, normal and abnormal MII, and fertilized oocytes, the number of transferred embryos (grades I, II and III), and biochemical and clinical pregnancy rates as well as the ovarian hyperstimulation syndrome (OHSS) were evaluated.

Results

There was a significant reduction in the serum levels of Insulin and total testosterone in the treated groups compared with the placebo. The number of mature and normal MII oocytes increased significantly in the treated groups compared with the placebo. Moreover, the number of immature oocytes decreased significantly and the number of grade I embryos increases significantly in the sitagliptin group compared with the placebo group.

Conclusion

We conclude that sitagliptin can improve the maturation of oocytes and embryos’ quality more effectively than metformin, in PCOS patients undergoing ICSI.

Trial registration

Trial registration is NCT04268563 (https://clinicaltrials.gov).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The data will be made available for researchers working in academic and scientific institutions upon request.

References

  1. Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y (2010) Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 57:667–672

    Article  CAS  Google Scholar 

  2. Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, Stener-Victorin E, Fauser BCJM, Norman RJ, Teede H (2016) The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 22(6):687–708

    Article  Google Scholar 

  3. Blauschmidt S, Greither T, Lampe K, Köller S, Kaltwaßer P, Behre HM (2017) Dipeptidyl peptidase 4 serum activity and concentration are increased in women with polycystic ovary syndrome. Clin Endocrinol 87(6):741–747

    Article  CAS  Google Scholar 

  4. Brezinova J, Oborna I, Svobodova M, Fingerova H (2009) Evaluation of day one embryo quality and IVF outcome–a comparison of two scoring systems. Reprod Biol Endocrinol 7(1):9

    Article  Google Scholar 

  5. Carani AV, Dipti N (2019) Sitagliptin recuperates oxidative stress and inflammatory cytokine expression in ovary of PCOS rats. J Drug Deliv Ther 9(4-s):244–251

    Article  Google Scholar 

  6. Cheraghi E, Mehranjani MS, Shariatzadeh MA, Esfahani MHN, Ebrahimi Z (2016) N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reprod Fertil Dev 28(6):723–731

    Article  CAS  Google Scholar 

  7. Cooper TG, Noonan E, Von Eckardstein S, Auger J, Baker HW, Behre HM et al (2010) World Health Organization reference values for human semen characteristics. Hum Reprod Update 16(3):231–245

    Article  Google Scholar 

  8. Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ (2020) Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 105(1):dgz028

    Article  Google Scholar 

  9. Dicker D (2011) DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 34(supplement 2):S276–S278

    Article  CAS  Google Scholar 

  10. Doldi N, Persico P, Di Sebastiano F, Marsiglio E, Ferrari A (2006) Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization–embryo transfer. Gynecol Endocrinol 22(5):235–238

    Article  Google Scholar 

  11. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G (2016) Poly cystic ovarian syndrome: an updated overview. Front Physiol 7:124

    Article  Google Scholar 

  12. El Omda F, Abd El Fattah A, Hashish M, Khalil M (2018) A randomized trial of combined letrozole with metformin versus clomiphene citrate with metformin in polycystic ovary (PCOS) patients. Egypt J Hosp Med 72(4):4382–4388

    Google Scholar 

  13. ESHRE/ASRM (2004) Rotterdam sponsored PCOS consensus workshop group revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

    Google Scholar 

  14. ESHRE/ASRM (2008) Thessaloniki sponsored PCOS consensus workshop group consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 23:462–477

    Article  Google Scholar 

  15. Ferjan S, Janez A, Jensterle M (2018) DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocr Pract 24(1):69–77

    Article  Google Scholar 

  16. Germeyer A, Jauckus J, Zorn M, Toth B, Capp E, Strowitzki T (2011) Metformin modulates IL-8, IL-1β, ICAM and IGFBP-1 expression in human endometrial stromal cells. Reprod BioMed Online 22(4):327–334

    Article  CAS  Google Scholar 

  17. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia 55(6):1577–1596

    Article  CAS  Google Scholar 

  18. Jacob, S. L., Brewer, C., Tang, T., Picton, H. M., Barth, J. H., & Balen, A. H. (2016). A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction, 1-9

  19. Jinno M, Takeuchi M, Watanabe A, Hirohama J, Hiura R, Suciu N (2012) A novel therapy with sitagliptin for metformin-ineffective aged ART repeaters: dramatical increase in pregnancy rate by decreasing postprandial glycemic levels and advanced glycation end-products. Fertil Steril 98(3):S174

    Article  Google Scholar 

  20. Kalem MN, Kalem Z, Gurgan T (2017) Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles. J Endocrinol Investig 40(7):745–752

    Article  CAS  Google Scholar 

  21. Kjøtrød SB, Carlsen SM, Rasmussen PE, Holst-Larsen T, Mellembakken J, Thurin-Kjellberg A et al (2011) Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-Centre study. Hum Reprod 26(8):2045–2053

    Article  Google Scholar 

  22. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R (2016) Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 106(1):6–15

    Article  Google Scholar 

  23. Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S, Dandona P (2012) Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 97(9):3333–3341

    Article  CAS  Google Scholar 

  24. Maruthini D, Harris SE, Barth JH, Balen AH, Campbell BK, Picton HM (2014) The effect of metformin treatment in vivo on acute and long-term energy metabolism and progesterone production in vitro by granulosa cells from women with polycystic ovary syndrome. Hum Reprod 29(10):2302–2316

    Article  CAS  Google Scholar 

  25. Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, Shu H, Liu Y, Li CL (2013) The human glucagonlike peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides 39:71–79

    Article  CAS  Google Scholar 

  26. Morin-Papunen L, Rantala AS, Unkila-Kallio L, Tiitinen A, Hippeläinen M, Perheentupa A, Tinkanen H, Bloigu R, Puukka K, Ruokonen A, Tapanainen JS (2012) Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol 97(5):1492–1500

    Article  CAS  Google Scholar 

  27. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52(1):17–30

    Article  CAS  Google Scholar 

  28. National Institutes of Health. Evidence-based methodology workshop onpolycystic ovary syndrome, December 3-5, 2012. Executive summary. Available at: https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf. Accessed March 1, 2016.

  29. Öztürk B, Gürbüz AS, Durak ZE, Öztürk HS (2019) Dipeptidyl peptidase-4 and adenosine deaminase enzyme levels in polycystic ovary syndrome. Gynecol Endocrinol 35(2):138–141

    Article  Google Scholar 

  30. Palma JP, Byhen EL, Ibánez L, Macedo LB, Palma CP, Velázquez CR (2018) Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: a pilot study. Revista Médica del Hospital General de México 81(1):15–26

    Article  Google Scholar 

  31. Rienzi L, Balaban B, Ebner T, Mandelbaum J (2012) The oocyte. Hum Reprod 27(Suppl. 1):i2–i21

    Article  Google Scholar 

  32. Romaní-Pérez M, Outeiriño-Iglesias V, Moya CM, Santisteban P, González-Matías LC, Vigo E, Mallo F (2015) Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology 156(10):3559–3569

    Article  Google Scholar 

  33. Salvatore, T., Nevola, R., Pafundi, P. C., Monaco, L., Ricozzi, C., Imbriani, S., ... & Sasso, F. C. (2019). Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. Nutrients, 11(8), 1878

  34. Scheen AJ (2008) New therapeutic approaches in type 2 diabetes. Int J Clin Lab Med 63(6):402–407

    CAS  Google Scholar 

  35. Singh B, Panda S, Nanda R, Pati S, Mangaraj M, Sahu PK, Mohapatra PC (2010) Effect of metformin on hormonal and biochemical profile in PCOS before and after therapy. Indian J Clin Biochem 25(4):367–370

    Article  CAS  Google Scholar 

  36. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM (2001) Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 75(3):505–509

    Article  CAS  Google Scholar 

  37. Tang, T., Glanville, J., Orsi, N., Barth, J. H., & Balen, A. H. (2006). The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction, 21(6), 1416–1425

  38. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, ... & Guideline Development Groups. (2011). Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust, 195, S65-S112

  39. Trümper A, Trümper K, Trusheim H, Arnold R, Göke B, Hörsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Molecular endocrinology 2001; 15: 1559–1570.

  40. Urman B, Tiras B, Yakin K (2004) Assisted reproduction in the treatment of polycystic ovarian syndrome. Reprod BioMed Online 8(4):419–430

    Article  Google Scholar 

  41. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker P (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47:478–487

    Article  CAS  Google Scholar 

  42. Wang F, Zhang ZF, He YR, Wu HY, Wei SS (2019) Effects of dipeptidyl peptidase-4 inhibitors on transforming growth factor-β1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats. J Obstet Gynaecol Res 45(3):600–608

    Article  CAS  Google Scholar 

  43. Yaralı H, Yıldız BO, Demirol A, Zeyneloğlu HB, Yiğit N, Bükülmez O, Koray Z (2002) Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 17(2):289–294

    Article  Google Scholar 

Download references

Acknowledgments

The authors thank the Infertility clinic of Mahdiyeh Educational Hospital (Tehran, Iran) and also the research laboratory of Arak University (Arak, Iran).

Funding

This study was financially supported by the Arak University and the Men’s Health and Reproductive Health Research Center of Shahid Beheshti University of Medical Sciences.

Author information

Authors and Affiliations

  1. Department of Biologyt, Faculty of Science, Arak University, Arak, Iran

    Delbar Daneshjou, Malek Soleimani Mehranjani & Seyed Mohammad Ali Shariat zadeh

  2. Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Shahrzad Zadeh Modarres

Authors
  1. Delbar Daneshjou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shahrzad Zadeh Modarres
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Malek Soleimani Mehranjani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyed Mohammad Ali Shariat zadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malek Soleimani Mehranjani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

The study was approved by the ethics committee of Shahid Beheshti University of Medical Sciences, Iran (IR.SBMU.RETECH.REC.1396.424).

Consent to participate

A written informed consent was obtained from patients.

Consent for publication

The authors, including Delbar Daneshjou, Shahrzad Zadeh Modarres, Malek Soleimani Mehranjani, and Mohammad Ali Shariatzadeh, agree to publish this article.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daneshjou, D., Zadeh Modarres, S., Soleimani Mehranjani, M. et al. Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI. Ir J Med Sci 190, 685–692 (2021). https://doi.org/10.1007/s11845-020-02320-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-020-02320-5

Keywords

Search

Navigation